BridgeBio Pharma, Inc. Cost of Goods and Services Sold
BridgeBio Pharma, Inc. (BBIO) reported Cost of Goods and Services Sold of $2.73 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-25.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2022-02-25
- BridgeBio Pharma, Inc. cost of goods and services sold for the quarter ending 2021-12-31 was $1.17M.
- BridgeBio Pharma, Inc. cost of goods and services sold for the quarter ending 2021-09-30 was $1.45M.
- BridgeBio Pharma, Inc. cost of goods and services sold for the quarter ending 2021-06-30 was $109.00K.
- BridgeBio Pharma, Inc. cost of goods and services sold for the quarter ending 2021-03-31 was $0.00.
- BridgeBio Pharma, Inc. cost of goods and services sold for fiscal 2021 was $2.73M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2021-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $2.63M derived: sum of 2 quarters · filed 2022-02-25 | $2.73M derived: sum of 3 quarters · filed 2022-02-25 | $2.73M 10-K · filed 2022-02-25 |
| 2021-09-30 | $1.45M 10-Q · filed 2021-11-04 | $1.56M derived: sum of 2 quarters · filed 2021-11-04 | $1.56M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $109.00K 10-Q · filed 2021-08-05 | $109.00K 10-Q · filed 2021-08-05 | ||
| 2021-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2022-02-25 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |